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Background: Patients with cyanotic congenital heart disease (CCHD) may have a low burden of
atherosclerosis. Endothelial dysfunction is an early stage of atherosclerosis and endothelial function is
previously studied in smaller CCHD groups with different techniques and variable results. We aimed
to examine endothelial function and carotid atherosclerosis in a larger group of CCHD patients.
Methods: This multicentre study assessed endothelial function in adults with CCHD and controls by mea-
suring the dilatory response of the brachial artery to post-ischemic hyperaemia (endothelium-dependent
flow-mediated-vasodilatation (FMD)), and to nitroglycerin (endothelium-independent nitroglycerin-
induced dilatation (NID)). Flow was measured at baseline and after ischaemia (reactive hyperaemia).
Carotid-intima-media-thickness (CIMT), prevalence of carotid plaque and plaque thickness (cPT-max)
were evaluated ultrasonographically. Lipoproteins, inflammatory and vascular markers, including
sphingosine-1-phosphate (S1P) were measured.
Results: Forty-five patients with CCHD (median age 50 years) and 45 matched controls (median age
52 years) were included. The patients presented with lower reactive hyperaemia (409 ± 114% vs.
611 ± 248%, p < 0.0001), however preserved FMD response compared to controls (106.5 ± 8.3% vs. 106.
4 ± 6.1%, p = 0.95). In contrast, NID was lower in the patients (110.5 ± 6.1% vs. 115.1 ± 7.4%,
p = 0.053). There was no difference in CIMT, carotid plaque or cPT-max. The patients presented with
lower high-density-lipoprotein cholesterol, and higher level of inflammatory markers and S1P.
Conclusion: Adults with CCHD had preserved FMD in the brachial artery, but impaired NID response and
lower reactive hyperaemia than controls. The preserved FMD and the comparable prevalence of carotid
atherosclerosis indicate that CCHD patients have the same risk of atherosclerosis as controls.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Patients with cyanotic congenital heart disease (CCHD) are
often stated to be at reduced risk of developing clinical manifesta-tions of atherosclerosis, although documentation for this remains
scarce [1–4]. A lower risk of atherosclerosis could be related to bet-
ter risk profile, but also to protective mechanisms induced by cya-
nosis and biochemical and physical adaptations secondary to
chronic hypoxemia [1–5]. Thus, secondary erythrocytosis, throm-
bocytopenia, hyperbilirubinaemia are thought to alter the
atherosclerotic process and to modify the distribution of lipopro-
teins beneficially and thereby decrease atherosclerotic plaque for-
mation [1–5]. The high-density-lipoprotein (HDL) associated
apolipoprotein-M (apoM)-sphingosine-1-phosphate (S1P) complex
J.B. Tarp et al. IJC Heart & Vasculature 30 (2020) 100632protects the endothelium [6,7] and low S1P levels have been
shown to link to an increased risk of atherosclerosis [8,9]. As it is
synthesized by the erythrocytes, CCHD patients with secondary
erythrocytosis may have elevated S1P levels and thus a relatively
protected vasculature.
The endothelium is a major regulator of vascular homeostasis,
maintaining an antithrombotic milieu and the balance between
vasodilatation and vasoconstriction [10]. Damage to the endothe-
lium promotes the entry of circulating inflammatory cells which
leads to lipid deposition and fibrosis [11]. Endothelial dysfunction
is therefore considered an early stage of atherosclerosis [10,12,13].
If CCHD patients are at reduced risk of atherosclerosis, endothelial
dysfunction would be a rarer phenomenon than otherwise
expected. Likewise, atherosclerotic markers in the carotid artery,
e.g. increased intima media thickness (CIMT) would be less
evident.
The present study aimed to investigate the conduit arteries in
patients with CCHD for early markers of atherosclerosis, i.e. vascu-
lar function in the brachial artery and intimal lesions in the carotid
artery.2. Methods
2.1. Study participants
Clinically stable adults with CCHD followed at The University
Hospitals in Copenhagen and Aarhus, (Denmark), Lund and Stock-
holm (Sweden), Oslo (Norway), and at The Royal Prince Alfred
Hospital in Sydney (Australia), were invited to participate.
CCHD was defined as congenital heart lesions with significant
right-to-left shunting and systemic oxygen saturation below 92%
at rest and/or below 87% during exercise [14]. Healthy controls
were drafted from advertisements in Danish newspapers, and from
two local recruitment homepages (www.sundhed.dk and
www.forsøgspersoner.dk). One to one matching was performed
for age (±five years), gender, smoking status (current smoker, for-
mer smoker, or lifelong non-smoker) and body mass index (BMI)
(<25 kg/m2, 25 to 29 kg/m2, 30 kg/m2). None of the participants
were ongoing or recent pregnant, or had any symptoms of recent
infections.
The Nordic patients and all the controls were examined in
Copenhagen, whereas the remaining patients were tested in
Sydney.2.2. Clinical measures and risk factors
Resting heart rate, transcutaneous oxygen saturation, weight
and height were recorded. Patients on antihypertensive medica-
tions and patients with abnormal twenty-four-hour blood pressure
measurements (mean systolic blood pressure > 140 mmHg or a
mean diastolic pressure > 90 mmHg) were defined as having
hypertension. Risk factors for atherosclerotic cardiovascular dis-
ease (CVD), including hypercholesterolemia, hypertension, previ-
ous myocardial infarction, and stroke for the patients and all the
participants parents and siblings, were recorded. The subjects were
classified as current smokers or as non-smokers, and the number of
pack-years registered.
The Framingham Risk Score [15] was calculated for all partici-
pants from the following parameters: sex, age, diabetes mellitus,
smoking, blood pressure, total-cholesterol and HDL-cholesterol
and subjects were subsequently divided according to their derived
10 years risk of developing CVD into three subgroups: low (<10%),
medium (10–19%) and high risk (>20%) groups [15].2
2.3. Assessment of vascular function
Brachial artery dilatory responses to post-ischemic reactive
hyperaemia (endothelium-dependent flow-mediated vasodilata-
tion (FMD)), and to nitroglycerin (NTG) (endothelium-
independent nitroglycerin-induced vasodilatation (NID)) were
used as measures of vascular function [16]. Assessments were per-
formed with an Acuson 128XP/10TM, (USA) ultrasound system in
Denmark and a GE Vivid E9 ultrasound device in Australia. A video
recorder was connected to the ultrasound system and to a frame
grabber and an artificial neural network wall detection software
(Vessel Image Analysis (VIA)) [17]. The anterior and posterior walls
were identified and tracked automatically within a user-defined
region of interest. The arterial diameter was initially measured at
rest (mean over 30 s - baseline diameter 1). A pneumatic tourni-
quet placed below the antecubital fossa was then inflated for
4.5 min to a pressure of 250–300 mmHg distal to the scanned seg-
ment of the artery and then rapidly deflated to induce reactive
hyperaemia. The arterial diameter was measured continuously
for the first five minutes immediately after cuff release and the
maximal diameter was recorded. Ten minutes later a second base-
line diameter was measured (mean of 30 s -baseline diameter 2).
NTG (400 lg) was given sublingually, and the arterial diameter
measured continuously for ten minutes and the maximal diameter
acquired. FMD and NID were automatically calculated as the max-
imal flow and NTG induced arterial diameters as a percentage of
the baseline diameters -1 and 2, respectively.
Flow velocities were obtained from the centre of the artery with
pulsed-wave Doppler at a 70 angle. The velocity time integral
(VTI), i.e. the area under the velocity/time curve was measured
as the mean of four cycles at rest and within the first 60 s after cuff
release. Flow was calculated by multiplying VTI by the heart rate
by the vessel cross-sectional area (p  r2). Post-ischemic reactive
hyperaemia was calculated as the maximal flow in percentage of
baseline flow.
Participants were asked to avoid caffeine containing liquids and
smoking on the study day. Pulmonary vasodilators (advanced ther-
apy (AT)), i.e. endothelin receptor antagonists (ERA) and
phosphodiesterase-5-inhibitors (PDE-5-inhibitor) either as
monotherapy or combined were paused 12 h before the assess-
ment. As NTG is considered contraindicated in patients treated
with PDE-5-inhibitors, these subjects were excluded from the
NTG challenge.2.4. Carotid ultrasound scanning
B-mode ultrasound scans were performed as previously
described [18]. CIMT was measured as the mean CIMT on the far
wall in 1 cm lengths of the common carotid artery either immedi-
ately proximal to the bifurcation or where measured thickest
[18,19]. Carotid plaques were defined as previous described [19].
An experienced vascular surgeon re-evaluated the plaque and
maximum plaque thickness (cPT-max) if identified.2.5. Blood and urine measurements
Lipoproteins, haematology and inflammatory markers were
determined in both study centres in non-fasting blood samples
by local standard laboratory methods and assays. Plasma S1P and
apoMwere measured as previously reported [20,21], but only done
in subjects examined in Denmark. Urine spot samples were anal-
ysed for albuminuria, defined as an albumin-creatinine
ratio  30 mg/g.
Table 1
Demographics.
Characteristics CCHD
patients
(n = 45)
Controls
(n = 45)
p-value
Clinical data
Age (years), median (IQR) 50.0 [47–55] 52.0 [44–
57]
0.8
Gender (female), n (%) 24 (53) 24 (53) 1.0
Systolic blood pressure, average 24 h
(mmHg), mean (±SD)
114 (±13) 120 (±17) 0.08
Diastolic blood pressure, average
24 h (mmHg), mean (±SD)
69 (±9) 75 (±11) 0.01
Heart rate (bpm), mean (±SD) 76 (±15) 63 (±11) <0.0001
Oxygen saturation at rest, (%),
median (IQR)
84 (81–88) 98.5 (98–
99)
<0.0001
Body mass index (kg/m2), mean
(±SD)
23.6 (±4.3) 24.6
(±3.8)
0.3
Congenital heart disease diagnoses
Ventricular septal defect, n (%) 24 (53) 0
Atrial septal defect, n (%) 6 (13) 0
Atrioventricular septal defect, n (%) 3 (7) 0
Persistent ductus arteriosus n, (%) 1 (2) 0
Tetralogy of Fallot, n (%) 3 (7) 0
Univentricular heart, n (%) 3 (7) 0
Double Outlet Right Ventricle, n (%) 2 (5) 0
Ebstein anomaly with atrial septal
defect, n (%)
1 (2) 0
Hemitruncus arteriosus, n (%) 1 (2) 0
Pulmonary arterio-venous
malformation, n (%)
1 (2) 0
Additional diagnoses
Diabetes mellitus, n (%) 2 (4) 0 0.5
Stroke, n (%) 9 (20) 0 0.003
Transient ischemic attacks, n (%) 2 (4) 0 0.5
Family history of CVD, n (%) 30 (67) 33 (73) 0.6
Current smoker, n (%) 4 (9) 3 (7) 0.7
Pack years, median [IQR] 22 [10–39] 30 [4–35] 0.9
Medications
Statins, n (%) 2 (4.4) 1 (2.2) 0.57
Advanced therapy for pulmonary
arterial hypertension, n (%)
35 (78) 0 (0) <0.0001
Endothelin receptor antagonist, n (%) 33 (73) 0 (0) <0.0001
Phosphodiesterase 5 inhibitor, n (%) 18 (40) 0 (0) <0.0001
Framingham 10-year CVD risk
score
0.6
Low (<10%), n (%) 29 (78) 39 (87)
Moderate (10–19%), n (%) 6 (16) 5 (11)
High (20%), n (%) 2 (6) 1 (2)
Carotid artery
Presence of carotid plaque, n (%) 11 (24) 7 (16) 0.27
cPT-max (mm), median [IQR] 2.2 [1.2–2.9] 2.8 [1.8–
6.7]
0.16
CIMT (mm), mean (±SD) 0.61 (±0.13) 0.64
(±0.13)
0.29
CCHD = Cyanotic congenital heart disease, bpm = beats per minutes, CVD = cardio-
vascular disease, CIMT = carotid intima media thickness, cPT-max = maximum
plaque thickness.
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Throughout, continuous variables were expressed as
means ± standard deviations (SD) if normally distributed and
otherwise as medians [25–75 percentiles], whereas categorical
variables were presented as numbers (percentages). For continu-
ous variables, unpaired comparisons between patients and con-
trols were performed using the Student’s t-test if normally
distributed or the Wilcoxon test if otherwise. The Chi-square or
Fisher’s exact test was used to compare categorical data as
appropriate.
Comparison of FMD and NID between the patients and controls
were performed primarily by application of the unpaired Student’s
t-test. As a sensitivity analysis, the same analyses were performed
by application of the paired Student’s t-test.
To identify potential confounding factors, univariable regres-
sion analyses were applied for each of the potential confounders
(Table 3). Factors with a p-value < 0.1 were included in a final mul-
tivariable regression model including FMD/NID as outcome, type of
participants (patient/control) as independent variable of interest
and potential confounders as covariates, including the matching
parameters: age, sex, BMI and smoking. Interaction terms between
type of participant and other covariates were included in the final
model if p-value for the interaction terms was below 0.05.
To test if treatment with vasoactive medications were possible
confounders, a multivariable regression model was applied with
FMD as outcome and AT (either ERA or PDE-5-inhibitor or both),
ERA and PDE-5-inhibitor as covariates. Further, a subgroup com-
parison with unpaired T-test was performed in patients not on
AT and their matched controls.
General linear models were applied to assess the associations
between cPT-max versus oxygen saturation in rest and proBNP
level and further between CIMT versus oxygen saturation in rest
and proBNP level and between left ventricular ejection fraction
(LVEF) and CIMT.
A p-value < 0.05 was considered statistically significant. Statis-
tical analyses were performed with the SAS statistic software ver-
sion 7.1.
2.7. Ethics
All participants signed a written informed consent form before
inclusion. The study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki as reflected in a priori approval by
the institution’s human research committee. The Danish (protocol
number: H-1-2014-035), the Norwegian (protocol number:
2014/2243/REK sør-øst A), the Swedish (protocol number:
2015/424-31) and the Australian (protocol number: HREC/16/
RPAH/135, 16-0109) ethic committees all approved the study
protocol.
3. Results
Forty-five patients with CCHD (53% women, median age
50 years) and 45 age-, BMI-, -sex, and smoking-matched subjects
(53% women, median age 52 years) were included. Thirty-five
(78%) of the CCHD patients were on AT; whereas 16 (36%) patients
received dual therapy (combination of ERA and PDE-5-inhibitor)
and 19 (42%) patients received mono-therapy (either ERA or
PDE-5-inhibitor). Baseline characteristics are shown in Table 1.
3.1. Assessment of vascular function
3.1.1. Endothelium dependent vasodilation
Baseline diameter-1 was similar in patients and controls (4.2 ±
0.8 mm vs. 4.1 ± 0.9 mm, p = 0.5), Table 2. There was no significant3
difference in FMD between patients with CCHD and controls (106.
5 ± 8.3% vs. 106.4 ± 6.1%, p = 0.95, [95% CI: 3.22 to 3.04%]). There
were no associations of any of the included covariates on FMD,
Table 3. Specifically, FMD was not associated with AT (ERA or/
and PDE-5-inhibitor). In a subgroup analysis with patients not
treated with pulmonary vasodilators and controls, FMD was simi-
lar in both groups (108.5 ± 11.1% vs 108.0 ± 8.8%, respectively,
p = 0.93).3.1.2. Brachial flow analysis
The baseline flow only tended to be higher in the CCHD patients
than controls (235 ± 108 ml/min vs 185 ± 128 ml/min, p = 0.06),
while the increase in flow-velocity was significantly lower in the
Table 2
Vascular parameters.
Vessel characteristic CCHD
patients
Controls p-value
Baseline diameter (mm), mean (±SD) 4.2 ± 0.8 4.1 ± 0.9 0.5
Flow velocity time integral, mean
(±SD)
16.0 ± 5.8 13 ± 6.5 <0.05
Baseline flow (mL/min), mean (±SD) 235 ± 108 185 ± 128 0.06
Flow increase, mean (±SD) 409 ± 114 611 ± 248 <0.0001
FMD (%), mean (±SD) 106.5 ± 8.3 106.4 ± 6.1 0.95
NID (%), mean (±SD) 111 ± 6 115 ± 7 0.05
CCHD = cyanotic congenital heart disease, FMD = flow mediated dilatation,
NID = nitroglycerin induced dilatation.
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p < 0.0001), Table 2.
The sensitivity analysis confirmed the above-mentioned results
in FMD and flow increase.
3.1.3. Endothelium independent vasodilation
Eighteen patients (44% women, median age 49.0 years, IQR:
44.0–53.0 years) and 18 matched controls (44% women, median
age 50.0 years, IQR: 39.0–53.0 years) with similar baseline diame-
ter (4.18 ± 0.83 mm vs. 4.26 ± 0.93 mm, p = 0.8) were tested after
NTG. The NID response was marginally, albeit not significantly,
lower in the CCHD patients when unpaired comparison was per-
formed (110.5 ± 6.1% vs. 115.1 ± 7.4%, p = 0.053), Table 2. However,
the sensitivity analysis with paired comparison of NID revealed a
significant difference between the two groups (p = 0.03). On uni-
variate analysis, NID was only associated with sex (p < 0.03),
Table 3.
3.2. Carotid artery analysis
There was no difference in CIMT (0.61 ± 0.13 mm vs. 0.64 ± 0.
13 mm, p = 0.3), prevalence of plaques (11/45 (24%) vs. 7/45
(16%), p = 0.27) or cPT-max (2.2 mm [1.2–2.9 mm] vs. 2.8 mm
[1.8–6.7 mm], p = 0.16) between patients and controls, Table 1.
No associations were found between LVEF and CIMT (-18.75 [CITable 3
Univariable and multiple logistic regression analyses.
Variables Univariable analyses
b ± SE
FMD
Type of participant (control) 0.1 ± 1.6
Age 0.0 ± 0.1
Sex (male) 2.8 ± 1.5
BMI 0.2 ± 0.2
Smoking (No) 1.8 ± 2.3
S1P 1.1 ± 3.1
HDL cholesterol 0.3 ± 1.7
LDL cholesterol 1.2 ± 0.9
Albuminuria 3.3 ± 1.8
Baseline vessel diameter 0.3 ± 1.0
NID
Type of participant (control) 4.6 ± 2.3
Age 0.1 ± 0.1
Sex (male) 5.0 ± 2.3
BMI 0.1 ± 0.3
Smoking (No) 2.5 ± 4.3
S1P 0.3 ± 2.9
HDL cholesterol 1.2 ± 3.6
LDL cholesterol 1.4 ± 1.2
Albuminuria 0.2 ± 2.8
Baseline vessel diameter 1.3 ± 1.4
FMD = flow mediated vasodilatation, BMI = body mass index, S1P: sphingosine-1-phos
urine-albumin/creatinine > 30 mg/g.
4
95%: 46.1; 8.6], p = 0.17). There was no difference in FMD
between the subjects with or without a carotid plaque (p = 0.9)
No associations were found between cPT-max versus oxygen
saturation in rest (0.082 [CI95%: 0.03; 0.19], p = 0.14) or between
cPT-max versus proBNP (0.0009 [CI95%: 0.005; 0.006], p = 0.76)
or between CIMT versus oxygen saturation in rest (0.0001
[CI95%: 0.008; 0.008], p = 0.97) or between CIMT and proBNP
level (0.0002 [CI95%: 0.0001; 0.0005], p = 0.18).3.3. Atherosclerotic, endothelial and inflammatory markers
The patients with CCHD had higher levels of inflammatory
markers (CRP: p = 0.02, leucocytes: p = 0.04, neutrophils:
p = 0.01, and HsCRP: p = 0.02), homocysteine: p < 0.0001) as well
as of Hb1AC (p = 0.0001), Table 4. There were no differences in
total-cholesterol or LDL-cholesterol, whereas HDL-cholesterol
was significantly lower in the patients (1.36 ± 0.47 mmol/L vs. 1.
76 ± 0.45 mmol/L, p = 0.0003), Table 4. The patients had higher
S1P (0.74 ± 0.48 mmol/L vs. 0.51 ± 0.18 mmol/L, p = 0.04) and lower
apoM (1.00 ± 0.59 mmol/L vs. 1.39 ± 0.51 mmol/L, p = 0.02).4. Discussion
The present study showed that flow-mediated dilatation (FMD),
a gold standard for assessment of endothelial function in conduit
arteries [13], was preserved in our cohort of adults with CCHD. It
also showed that parameters of carotid atherosclerosis (CIMT, pla-
que burden or cPT-max) were comparable to that seen in matched
healthy controls. The normal FMD combined with the similar car-
otid parameters, indicates that patients with CCHD do not seem to
have different conduit artery physiology and pathology, i.e. the
same atherosclerotic burden as healthy controls, despite exposed
to abnormal levels of pro-atherosclerotic factors, including higher
inflammatory markers and HbA1c levels as well as to lower HDL-
cholesterol levels.
Previous studies have addressed endothelial function in CCHD
patients in different age-groups, with different techniques and
with diverging results [5,22–25]. In four studies, brachial arteryMultivariable analyses
p-value partial r2 p-value
0.96 1.5 ± 1.7 0.41
0.76 0.0 ± 0.1 0.81
0.07 3.0 ± 1.6 0.07
0.41 0.1 ± 0.2 0.65
0.53 0.8 ± 2.9 0.78
0.73
0.85
0.17
0.08 4.3 ± 2.1 0.04
0.73
0.05 4.6 ± 2.3 0.05
0.57 0.1 ± 0.1 0.40
0.03 5.2 ± 2.3 0.03
0.84 0.0 ± 0.3 0.99
0.57 0.2 ± 4.4 0.97
0.93
0.74
0.25
0.93
0.37
phate, HDL: high-density-lipoprotein, LDL = low density lipoprotein, Albuminuria:
Table 4
Biochemistry.
Parameters CCHD patients Control p-value
Haematocrit (%), median (IQR) 0.58 (0.53–0.63) 0.42 (0.38–0.44) <0.0001
Haemoglobin (mmol/L), median (IQR) 12.0 (11.1–12.9) 8.7 (8.2–9.2) <0.0001
Platelets (109/L), mean (±SD) 171.0 (±55.9) 241.3 (±52.9) <0.0001
CRP (mg/L), median [p25-p75] 2.9 [1.0–5.5] 1.0 [1.0–2.5] 0.02
Leukocytes (109/L), mean (±SD) 6.77 (±1.56) 6.02 (±1.90) 0.04
Neutrophils (109/L), mean (±SD) 4.41(±1.23) 3.65 (±1.64) 0.01
Creatinine (mmol/L), mean (±SD) 80.5(±23.5) 77.4 (±14.1) 0.5
ProBNP (pmol/L), mean (±SD) 104.9 (±134.7) 6.6 (±8.9) <0.0001
Total cholesterol (mmol/L), mean (±SD) 4.91 (±1.16) 5.29 (±0.90) 0.1
LDL cholesterol (mmol/L), mean (±SD) 3.03 (±1.01) 3.2 (±0.78) 0.4
HDL cholesterol (mmol/L), mean (±SD) 1.36 (±0.47) 1.76 (±0.45) 0.0003
Triglycerides (mmol/L), median [IQR] 1.38 [0.85–2.03] 1.0 [0.72–1.44] 0.02
Hb1AC (mmol/mol), mean (±SD) 37.7 (±3.9) 34.2 (±3.8) 0.0001
Homocysteine (mmol/L), mean (±SD) 18.3 (±6.7) 12.6 (±4.6) <0.0001
HsCRP (mg/L), median [IQR] 2.25 [1.0–4.7] 1.0 [0.6–2.0] 0.02
ApoM (mmol/L), mean (±SD) 1.00 (±0.59) 1.39 (±0.51) 0.02
S1P (mmol/L), mean (±SD) 0.74 (±0.48) 0.51(±0.18) 0.04
Albuminuria, % (n) 42 (19) 7 (3) 0.0001
CCHD = cyanotic congenital heart disease, IQR: interquartile range, SD = standard deviation, LDL = low density lipoprotein, HDL = high density lipoprotein,
HbA1C = haemoglobin A1C, apoM = apolipoprotein M, S1P = sphingosine-1-phosphate.
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including one in a paediatric cohort [5]. In the three adult studies
available, the patients included were marginally younger, but
otherwise comparable to our patients with regard to oxygen satu-
ration, haematocrit and haemoglobin level [22–24]. In one of these
studies, FMD was also found to be normal24 while two studies
reported significantly lower FMD in the CCHD patients [22,23].
The reason for this discrepancy is unclear, but in these studies, flow
and NID data were not provided. The evaluation of vascular func-
tion in the brachial artery not only includes FMD measures, but
also data on the post-ischemic hyperaemic response (the stimulus
for FMD) and on the vasodilatory NTG response (vascular smooth
cell function stimulus). The difference in FMD measures seen
between our study and the two studies, which did not include
these data, could therefore theoretically relate to differences in
the two vasomotor stimuli employed.
Unfortunately, our brachial data were somewhat heterogeneous
with a tendency to higher baseline flow velocities, reduced reactive
hyperaemic flow velocities, and NID responses that tended to be
lower than in controls. The reason for this remains unclear. A high
number of patients were on pulmonary vasodilators, which may
influence vascular function, although the ‘‘post-hoc” analysis did
suggest this effect to be absent or small. Some of the observations
may suggest that patients with CCHD have more baseline NO
release from their endothelium. A more ‘‘tonic” NO release would
in full extent lead to higher flow, bigger vessels and a lower ‘‘va-
sodilator reserve” to NTG, as there is already more baseline NO
secretion. Apart from the non-significant difference in vessel size,
this explanation remains possible. If so, the trigger for a higher
NO production could be increased wall shear-stress secondary to
the erythrocytosis seen in the CCHD patients [26].
The combined observation of preserved FMD, reduced post-
ischemic flow velocities and borderline lower NID responses in
the CCHD group, may also suggest discordant vasomotor responses
in the conduit arteries and in the microcirculation. This is in line
with observations from Oechslin et al. They measured forearm
blood flow with plethysmography and found lower baseline blood
flow and a reduced response to intra-arterial infusion of acetyl-
choline in CCHD patients compared to controls indicating
microvascular endothelial dysfunction. However, the
endothelium-independent vasodilatation was preserved as also
seen in the present study [25].5
Endothelial function measured by FMD varies considerable
from study to study. A large meta-analysis demonstrated that
FMD ranges between 2.3 and 13.5 % among diseased and asymp-
tomatic populations, as well as an inverse relationship exists
between the risk of CVD and FMD [27]. FMD below 4.7% has been
found associated with a higher probability of CVD [28]. Four out of
five studies assessing FMD among patients with CCHD, including
the present study, shows a FMD above 5.0%, hence in the higher
end of the FMD spectrum [5,23,24]. This may be interpreted as
patients with CCHD have a better endothelial function than
patients with a high risk of CVD.
S1P is known to induce angiogenesis and the higher levels seen
in the CCHD patients may therefore play a major role for eventual
remodelling of the microvasculature [6,20]. S1P activates eNOS and
is linked to NO production [29]. However, the increased S1P levels
seen in our CCHD patients, were not reflected in an increased FMD
and no association between S1P and FMD was found. Interestingly,
plasma S1P is transported mainly by apoM-containing HDL parti-
cles (70%), and to a minor extend by albumin (30%) [6,7]. S1P-
ApoM is the main plasma component that can activate the S1P-
receptors on the vessel wall [20,30]. Hence, S1P-albumin alone
cannot protect and maintain normal vascular barrier integrity.
The increased plasma S1P in the patients with CCHD, may predom-
inantly be bound in the S1P-albumin complex since both the levels
of apoM and HDL-cholesterol were low in the patients. A high con-
centration of S1P in the S1P-albumin complex does not represent a
more protected endothelium, and a higher plasma S1P in CCHD
patients will maybe not contribute beneficially to endothelium
protection.
Previous studies included patients with pulmonary hyperten-
sion, but not those on pulmonary vasodilators. In the present
study, 78% of the patients were on AT. Since these probably repre-
sent the most ill patients, one would have expected detectable
endothelial dysfunction if patients with CCHD were prone to
develop atherosclerosis. This was not the case. The medications
could theoretically affect the measured vascular parameters,
although in the opposite direction. ERAs will thus tend to increase
resting vessel size, and hence attenuate FMD which is highly
related to vessel size [11]. PDE-5-inhibitors block the breakdown
of c-GMP, which would enhance the effect of the NO released in
response to the reactive hyperaemia. The plasma half time of
Bosentan and Sildenafil are approximately five hours, and it there-
J.B. Tarp et al. IJC Heart & Vasculature 30 (2020) 100632fore seemed sufficient to minimize the possible acute effect on
FMD by pausing the medication for 12 h prior to the assessment,
although this may not change the more long-time effect. These
considerations are supported by the lack of difference in baseline
diameter of the brachial artery between CCHD patients and con-
trols, by the identical FMD of patients and controls in a subgroup
analysis where the patients were not on AT, and lastly by the lack
of association between AT and FMD.
The carotid parameters showed no difference in CIMT, preva-
lence of plaque or cPT-max between patients and controls. This
is similar to previously reported data in paediatric patients [5]
but in contrast to the only available study in adults with CCHD
which found a lower CIMT in the patients [2]. Plaque data have
previously not been reported. We not only found similar CIMT in
the two groups, but also an equivalent overall plaque burden.
The results hereby provide a thorough assessment of the carotid
arteries showing the same prevalence of atherosclerosis in patients
with CCHD as in matched controls.
Atherosclerotic disease progresses with advancing age. The age
difference between the present study (median 50.0 years) and the
study by Duffel et al. (mean age 38 years) may partly explain the
difference in CIMT between the two patient cohorts, who other-
wise may be assumed to present with the same conduit artery
physiology and pathology [2].
5. Limitations
We did not match women for day of menstrual cycle and only
asked the participants to avoid caffeine containing liquids and
smoking on day of examination. This might have some impact on
the results but are unlikely to affect the group comparisons or
the conclusions drawn. Investigations were performed in two dif-
ferent centres (eight patients in Sydney and 37 patients and all
controls in Denmark). Both centres used the same protocol and
the assessments were performed by trained staff. This set-up
potentially introduces some variability [13]. Finally, 78% of the
patients were on AT which, as eluded to above, could introduce
some bias.
6. Conclusion
Brachial artery FMD is preserved in adults with CCHD. Increased
resting flow velocities and attenuated reactive hyperaemia may
reflect functional remodelling and perhaps endothelial dysfunction
in the microvasculature. Although the CCHD patients presented
with higher levels of inflammatory markers and lower HDL-
cholesterol levels, no difference in the prevalence or degree of car-
otid atherosclerosis was found. The results indicate that patients
with CCHD may have a similar risk of developing atherosclerosis
as the background population.
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